Posted by Michael Wonder on 30 May 2019
NICE backs Merck's Prevymis for CMV
30 May 2019 - NICE has published its final appraisal document for the use of Merck's Prevymis (letermovir/ID1153) in preventing cytomegalovirus re-activation and disease in patients receiving an allogeneic stem cell transplant.
Prevymis, a member of a new class of drugs called non-nucleoside cytomegalovirus (CMV) inhibitors, is recommended by the cost watchdog for England, Wales and Northern Ireland, in adults who are seropositive for CMV.
The recommendation for the drug’s provision on the NHS comes after the US pharma giant came to a commercial agreement with the NICE.
